Tandem Diabetes Care, Inc. Stock News

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, IN...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TANDEM DIABETES CARE, INC. (TNDM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RE...

Downgrading Tandem Diabetes Care to sell after Q2 2025 earnings confirms core U.S. business weakness and deteriorating profitability. Intense competition from Insulet and Medtronic is eroding Tandem's market share, with rivals showing stronger growth and profitability. Management's credibility is under pressure, due to material guidance downgrades and reactive strategy, despite upcoming product...

Tandem Diabetes Care issued a voluntary correction for an insulin pump model due to a speaker malfunction that disrupts communication with glucose monitoring systems, potentially causing high blood sugar levels.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery. The error, which appears as a Malfunction 16 alarm to the user, will stop insulin delivery and terminate communicatio...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants John F. Sheridan - President, CEO & Director Leigh A.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance. Second Quarter 2025 Highlights Achieved record second quarter sales both in the United States (U.S.) and internationally. Demonstrated year-over-year and se...